BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zolacabtagene autoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zolacabtagene autoleucel\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06220201-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Zolacabtagene autoleucel: Phase 1 readout est. (NCT06220201)
DESCRIPTION:Zolacabtagene autoleucel\, phase 1.\nStudy: A Study to Evaluate
  the Safety\, Tolerability\, Efficacy\, and Drug Levels of CC-97540 in Par
 ticipants With Relapsing Forms of Multiple Sclerosis\, Progressive Forms o
 f Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)\nE
 stimated primary completion: 15 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06220201
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015983-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20280517
DTEND;VALUE=DATE:20280518
SUMMARY:Zolacabtagene autoleucel: Phase 2 readout est. (NCT07015983)
DESCRIPTION:Zolacabtagene autoleucel\, phase 2\, Systemic Lupus Erythematos
 us.\nStudy: A Study of CC-97540 (BMS-986353 or Zola-cel)\, CD19-Targeted N
 EX-T CAR T Cells\, in Participants With Active SLE Despite Immunosuppressa
 nts (Breakfree-SLE)\nEstimated primary completion: 17 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07015983
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869955-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20280829
DTEND;VALUE=DATE:20280830
SUMMARY:Zolacabtagene autoleucel: Phase 1 readout est. (NCT05869955)
DESCRIPTION:Zolacabtagene autoleucel\, phase 1\, Systemic Lupus Erythematos
 us.\nStudy: A Study of CC-97540\, CD-19-Targeted Nex-T CAR T Cells\, in Pa
 rticipants With Severe\, Refractory Autoimmune Diseases (Breakfree-1)\nEst
 imated primary completion: 29 August 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05869955
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335562-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Zolacabtagene autoleucel: Phase 3 readout est. (NCT07335562)
DESCRIPTION:Zolacabtagene autoleucel\, phase 3.\nStudy: A Study to Compare 
 the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-ce
 l)\, CD19-CAR T Cells\, Versus Standard of Care in Participants With Activ
 e Systemic Sclerosis\nEstimated primary completion: 14 November 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zolacabtagene-autoleucel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 5562
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388277-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zolacabtagene autoleucel: Phase 1/2 readout est. (NCT07388277)
DESCRIPTION:Zolacabtagene autoleucel\, phase 1/2.\nStudy: CC-97540 in Patie
 nts With Antineutrophil Cytoplasmic Antibody-associated Vasculitis\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07388277
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603557-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20300506
DTEND;VALUE=DATE:20300507
SUMMARY:Zolacabtagene autoleucel: Phase 2 readout est. (NCT07603557)
DESCRIPTION:Zolacabtagene autoleucel\, phase 2.\nStudy: Study of Zola-cel (
 BMS-986353)\, in Participants With Autoimmune Cytopenia (Breakfree-AiCE)\n
 Estimated primary completion: 6 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07603557
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573332-11187@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Zolacabtagene autoleucel: Phase 1 readout est. (NCT07573332)
DESCRIPTION:Zolacabtagene autoleucel\, phase 1.\nStudy: A Safety and Tolera
 bility Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positi
 ve Neuromyelitis Optica Patients\nEstimated primary completion: 1 August 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zolacabtagene-au
 toleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07573332
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
